FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050047704> ?p ?o ?g. }

• W2050047704 endingPage "2049" @default.
• W2050047704 startingPage "2042" @default.
• W2050047704 abstract "Objective Recurrent upper respiratory tract infections (URTIs) are common illnesses in young children. As the immunoactive bacterial extract OM-85 has been shown to prevent these infections in both adults and children, the aim of the present trial was to investigate further its efficacy and safety in infection-prone children. Methods This is a randomized, double-blind, placebo-controlled, multicenter study with OM-85 in 232 patients aged 36 to 96 months with recurrent URTIs. Treatment was one capsule daily during month 1 and during 10 days in months 3 to 5. URTI was defined by the presence of at least two of the following: rhinitis, pharyngitis, cough, hoarseness, temperature ≥ 38.5°C, or URTI-related prescription of an antibiotic. Results OM-85–treated patients had a lower rate of URTIs (p < 0.05). The cumulated difference in URTIs between the two groups reached − 0.40 URTIs per patient in 6 months, corresponding to a 16% reduction in the active-treatment group with respect to placebo. The largest difference was observed in the patients having had three or more URTIs during the study period; odds ratios for three or more URTIs were 0.51 (95% confidence interval, 0.29 to 0.91) and 0.65 (95% confidence interval, 0.37 to 1.11) after 5 months and 6 months, respectively. The difference between OM-85 and placebo was independent of age but was more important in patients reporting a larger number of URTIs in the previous year. Patients’ global assessment showed improvement in comparison to the previous season in the majority of the cases (OM-85, 78.4% of cases; placebo, 75.5%); however, there were more cases reporting worsening with placebo (6.4% vs 0.9%; p = 0.05). Conclusions OM-85 treatment significantly reduced the rate of URTIs, particularly in children with a history of frequent URTIs. Safety and tolerance of test medication were good, comparable to placebo. Recurrent upper respiratory tract infections (URTIs) are common illnesses in young children. As the immunoactive bacterial extract OM-85 has been shown to prevent these infections in both adults and children, the aim of the present trial was to investigate further its efficacy and safety in infection-prone children. This is a randomized, double-blind, placebo-controlled, multicenter study with OM-85 in 232 patients aged 36 to 96 months with recurrent URTIs. Treatment was one capsule daily during month 1 and during 10 days in months 3 to 5. URTI was defined by the presence of at least two of the following: rhinitis, pharyngitis, cough, hoarseness, temperature ≥ 38.5°C, or URTI-related prescription of an antibiotic. OM-85–treated patients had a lower rate of URTIs (p < 0.05). The cumulated difference in URTIs between the two groups reached − 0.40 URTIs per patient in 6 months, corresponding to a 16% reduction in the active-treatment group with respect to placebo. The largest difference was observed in the patients having had three or more URTIs during the study period; odds ratios for three or more URTIs were 0.51 (95% confidence interval, 0.29 to 0.91) and 0.65 (95% confidence interval, 0.37 to 1.11) after 5 months and 6 months, respectively. The difference between OM-85 and placebo was independent of age but was more important in patients reporting a larger number of URTIs in the previous year. Patients’ global assessment showed improvement in comparison to the previous season in the majority of the cases (OM-85, 78.4% of cases; placebo, 75.5%); however, there were more cases reporting worsening with placebo (6.4% vs 0.9%; p = 0.05). OM-85 treatment significantly reduced the rate of URTIs, particularly in children with a history of frequent URTIs. Safety and tolerance of test medication were good, comparable to placebo." @default.
• W2050047704 created "2016-06-24" @default.
• W2050047704 creator A5000138065 @default.
• W2050047704 creator A5034680690 @default.
• W2050047704 creator A5072122898 @default.
• W2050047704 date "2002-12-01" @default.
• W2050047704 modified "2023-10-06" @default.
• W2050047704 title "Immunostimulation with OM-85 in Children with Recurrent Infections of the Upper Respiratory Tract" @default.
• W2050047704 cites W1964935926 @default.
• W2050047704 cites W1967300438 @default.
• W2050047704 cites W1969934047 @default.
• W2050047704 cites W1991957164 @default.
• W2050047704 cites W2003519130 @default.
• W2050047704 cites W2012284731 @default.
• W2050047704 cites W2016736819 @default.
• W2050047704 cites W2051940625 @default.
• W2050047704 cites W2064758793 @default.
• W2050047704 cites W2071669558 @default.
• W2050047704 cites W2094161521 @default.
• W2050047704 cites W2114626700 @default.
• W2050047704 cites W2119986866 @default.
• W2050047704 cites W2125170970 @default.
• W2050047704 cites W2137407508 @default.
• W2050047704 doi "https://doi.org/10.1378/chest.122.6.2042" @default.
• W2050047704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12475845" @default.
• W2050047704 hasPublicationYear "2002" @default.
• W2050047704 type Work @default.
• W2050047704 sameAs 2050047704 @default.
• W2050047704 citedByCount "96" @default.
• W2050047704 countsByYear W20500477042012 @default.
• W2050047704 countsByYear W20500477042013 @default.
• W2050047704 countsByYear W20500477042014 @default.
• W2050047704 countsByYear W20500477042015 @default.
• W2050047704 countsByYear W20500477042016 @default.
• W2050047704 countsByYear W20500477042017 @default.
• W2050047704 countsByYear W20500477042018 @default.
• W2050047704 countsByYear W20500477042019 @default.
• W2050047704 countsByYear W20500477042020 @default.
• W2050047704 countsByYear W20500477042021 @default.
• W2050047704 countsByYear W20500477042022 @default.
• W2050047704 countsByYear W20500477042023 @default.
• W2050047704 crossrefType "journal-article" @default.
• W2050047704 hasAuthorship W2050047704A5000138065 @default.
• W2050047704 hasAuthorship W2050047704A5034680690 @default.
• W2050047704 hasAuthorship W2050047704A5072122898 @default.
• W2050047704 hasConcept C126322002 @default.
• W2050047704 hasConcept C142724271 @default.
• W2050047704 hasConcept C156957248 @default.
• W2050047704 hasConcept C168563851 @default.
• W2050047704 hasConcept C187212893 @default.
• W2050047704 hasConcept C203014093 @default.
• W2050047704 hasConcept C204787440 @default.
• W2050047704 hasConcept C2426938 @default.
• W2050047704 hasConcept C27081682 @default.
• W2050047704 hasConcept C2776012195 @default.
• W2050047704 hasConcept C2778136109 @default.
• W2050047704 hasConcept C2779279270 @default.
• W2050047704 hasConcept C2780805593 @default.
• W2050047704 hasConcept C2911094336 @default.
• W2050047704 hasConcept C44249647 @default.
• W2050047704 hasConcept C501593827 @default.
• W2050047704 hasConcept C534529494 @default.
• W2050047704 hasConcept C71924100 @default.
• W2050047704 hasConcept C86803240 @default.
• W2050047704 hasConcept C89423630 @default.
• W2050047704 hasConcept C98274493 @default.
• W2050047704 hasConceptScore W2050047704C126322002 @default.
• W2050047704 hasConceptScore W2050047704C142724271 @default.
• W2050047704 hasConceptScore W2050047704C156957248 @default.
• W2050047704 hasConceptScore W2050047704C168563851 @default.
• W2050047704 hasConceptScore W2050047704C187212893 @default.
• W2050047704 hasConceptScore W2050047704C203014093 @default.
• W2050047704 hasConceptScore W2050047704C204787440 @default.
• W2050047704 hasConceptScore W2050047704C2426938 @default.
• W2050047704 hasConceptScore W2050047704C27081682 @default.
• W2050047704 hasConceptScore W2050047704C2776012195 @default.
• W2050047704 hasConceptScore W2050047704C2778136109 @default.
• W2050047704 hasConceptScore W2050047704C2779279270 @default.
• W2050047704 hasConceptScore W2050047704C2780805593 @default.
• W2050047704 hasConceptScore W2050047704C2911094336 @default.
• W2050047704 hasConceptScore W2050047704C44249647 @default.
• W2050047704 hasConceptScore W2050047704C501593827 @default.
• W2050047704 hasConceptScore W2050047704C534529494 @default.
• W2050047704 hasConceptScore W2050047704C71924100 @default.
• W2050047704 hasConceptScore W2050047704C86803240 @default.
• W2050047704 hasConceptScore W2050047704C89423630 @default.
• W2050047704 hasConceptScore W2050047704C98274493 @default.
• W2050047704 hasIssue "6" @default.
• W2050047704 hasLocation W20500477041 @default.
• W2050047704 hasLocation W20500477042 @default.
• W2050047704 hasOpenAccess W2050047704 @default.
• W2050047704 hasPrimaryLocation W20500477041 @default.
• W2050047704 hasRelatedWork W1868281334 @default.
• W2050047704 hasRelatedWork W2050941802 @default.
• W2050047704 hasRelatedWork W2070836440 @default.
• W2050047704 hasRelatedWork W2410263914 @default.
• W2050047704 hasRelatedWork W2416675003 @default.
• W2050047704 hasRelatedWork W2955877479 @default.

• next